Skip to main content

Market Overview

Chinook Therapeutics Nabs Rare Pediatric Disease Tag For CHK-336 In Primary Hyperoxaluria

  • The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria (PH), a rare genetic disorder that mainly affects the kidneys and results from a buildup of a substance called oxalate.
  • Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or sold to a third party.
  • CHK-336 is currently progressing through IND-enabling studies, with a Phase 1 study planned for the second half of 2021.
  • Price Action: KDNY stock is up 3.52% at $15.89 on the last check Tuesday.
  • Related News: Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study

Related Articles (KDNY)

View Comments and Join the Discussion!

Posted-In: kidney disease Phase 1 TrialBiotech News Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at